Prediction of absorbed dose by tumors and critical organs after Lu-177-DOTATATE therapy using pretherapeutic Ga-68-DOTATOC PET/CT

被引：0
|
作者：
Kim, Yong-il [1 ]
Oh, Jungsu [1 ]
Yoo, Changhoon [1 ]
Ryoo, Baek-Yeol [1 ]
Ryu, Jin-Sook [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF NUCLEAR MEDICINE | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
76
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT
    Lee, Hwan
    Kipnis, Sarit T.
    Niman, Remy
    O'Brien, Sophia R.
    Eads, Jennifer R.
    Katona, Bryson W.
    Pryma, Daniel A.
    CANCERS, 2024, 16 (01)
  • [12] 68Ga DOTATOC PET/CT for treatment response of Peptide Receptor Radionuclide Therapy using 177Lu and 90Y-DOTATOC
    Finocchiaro, D.
    Grassi, E.
    Fioroni, F.
    Castellani, G.
    Lanconelli, N.
    Versari, A.
    Filice, A.
    Iori, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S288 - S288
  • [13] Diagnostic 68Ga-DOTATOC imaging parameters and correlations with absorbed dose from 177Lu-DOTATATE treatment in GEP-NET-patients
    Bruvoll, R.
    Blakkisrud, J.
    Mikaelsen, L.
    Connelly, J.
    Stokke, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S336 - S337
  • [14] Concordance between baseline 68Ga-DOTATOC PET/CT and first post-dose 177Lu-oxodotreotide SPECT/CT (177Lu-DOTATATE-SPECT/CT) images in patients with neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
    Cardozo Saavedra, A.
    Simo-Perdigo, M.
    Garcia-Burillo, A.
    Villasboas-Rosciolesi, D.
    Hernando, J.
    Capdevila, J.
    Menendez-Sanchez, S.
    Bellviure-Meiro, R.
    Dellepiane-Clarke, F.
    Aguade-Bruix, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S466 - S467
  • [15] 177Lu-DOTATATE (Lutathera) Therapy in 68Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor
    Ventura, David
    Roll, Wolfgang
    Kasper, Hans-Udo
    Rahbar, Kambiz
    Stegger, Lars
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : E585 - E587
  • [16] Semi-automated segmentation method of 68Ga-DOTATOC PET for dosimetry prediction in refractory meningiomas treated by 177Lu-DOTATATE
    Boursier, C.
    Zaragori, T.
    Bros, M.
    Mairal, E.
    Imbert, L.
    Verger, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S371 - S372
  • [17] Comparing 18F-DOPA and 68Ga-DOTATOC PET/CT imaging performance and its impact on 177 Lu-DOTATATE outcome in midgut neuroendocrine tumors
    Coccarelli, A.
    Henry, T.
    Longo, M.
    Khamoun, T.
    Morbelli, S.
    Lamartina, L.
    Pani, F.
    Moog, S.
    Hadoux, J.
    Baudin, E.
    Deandreis, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S516 - S516
  • [18] Testicular Metastasis From Neuroendocrine Tumors: Imaging and Theranostics Through 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE-Based Peptide Receptor Radionuclide Therapy
    Parghane, Rahul V.
    Basu, Sandip
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : 1051 - 1052
  • [19] Discordant Uptake Between Diagnostic 68Ga-HA-DOTATATE PET/CT and Posttherapy 177Lu-HA-DOTATATE SPECT/CT in Patients With Neuroendocrine Tumors
    Huizing, Daphne M. V.
    Aalbersberg, Else A.
    van der Hiel, Bernies
    Stokkel, Marcel P. M.
    Versleijen, Michelle W. J.
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E475 - E477
  • [20] Single-time-point [68Ga]Ga-DOTATATE-PET/CT for model-based prediction of the time-integrated activity of [177Lu]Lu-DOTATATE during therapy
    Vasic, V.
    Gustafsson, J.
    Yousefzadeh-Nowshahr, E.
    Beer, A.
    Gleisner, K. Sjoegreen
    Glatting, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S403 - S403
12345